ArticleBlood cancer discovery2021
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 56 citations in OpenAlex.
- Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.Cancer cell · 2026Article
- Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.Current hematologic malignancy reports · 2025Review
- Review
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation.ACS medicinal chemistry letters · 2025Article
- MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy.Cancer gene therapy · 2025Review
- Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome.Nature communications · 2025Article
- Genetic and environmental risks for clonal hematopoiesis and cancer.The Journal of experimental medicine · 2025Review
- Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024Review
- TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Clinical epigenetics · 2024Review
- RNA mNature · 2024Article
- Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate.Journal of medicinal chemistry · 2024Article
- TET2 mutation as prototypic clonal hematopoiesis lesion.Seminars in hematology · 2024Review
- TET (Ten-eleven translocation) family proteins: structure, biological functions and applications.Signal transduction and targeted therapy · 2023Review
- Article
- Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface.JCO precision oncology · 2023Review
- Article
- Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy.Biomedicines · 2023Review
- Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis.Frontiers in molecular biosciences · 2023Review
- Transcription factor genetics and biology in predisposition to bone marrow failure and hematological malignancy.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Yihong GuanDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.ORCID 0000-0001-8002-5141
Anand D TiwariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.ORCID 0000-0002-2038-5919
James G PhillipsDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Metis HasipekDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Dale R GrabowskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Simona PagliucaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Priyanka GopalDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Cassandra M KerrDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Vera AdemaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Tomas RadivoyevitchDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-9701-1851
Yvonne ParkerDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Daniel J LindnerDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.ORCID 0000-0002-8296-7703
Manja MeggendorferMunich Leukemia Laboratory, Munich, Germany.
Mohamed AbazeedDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.ORCID 0000-0002-6614-4440
Mikkeal A SekeresDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.
Omar Y MianDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio.ORCID 0000-0002-8133-8120
Torsten HaferlachMunich Leukemia Laboratory, Munich, Germany.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio. jhab@ccf.org maciejj@ccf.org.
Babal K JhaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio. jhab@ccf.org maciejj@ccf.org.ORCID 0000-0002-7660-5255
Translational Research in Oncology · FRCleveland Clinic · USCleveland Clinic Lerner College of Medicine · USMunich Leukemia Laboratory (Germany) · DE
Funding
Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7MTargeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid NeoplasmsR01CA257544 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI JHA, BABAL K, MACIEJEWSKI, JAROSLAW P. · 2021 to 2025
$3.0MA biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancerR37CA222294 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABAZEED, MOHAMED E. · 2018 to 2024
$2.5MNCI NIH HHS R01 CA257544NHLBI NIH HHS R35 HL135795
Abstract
PubMed holds no abstract for this paper.
Indexed as
DioxygenasesLeukemiaAnimalsDNA-Binding ProteinsHematopoiesisHumansMiceProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanTet2 protein, mouse2-hydroxygluterate5hmCIDHMDSTET2α-ketoglutarate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.